Blockchain Registration Transaction Record

Annovis Bio Presents Breakthrough Alzheimer's Study Results

Annovis Bio presents significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association International Conference(R) 2024 (AAIC(R)) in Philadelphia, showcasing the drug's potential to improve the quality of life for early Alzheimer’s patients and its effectiveness in treating Parkinson’s and Alzheimer’s diseases.

This news matters because Annovis Bio's lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients, offering hope for better treatment options. The study results also indicate the drug's effectiveness in treating both Parkinson’s and Alzheimer’s diseases, which could have a profound impact on patients suffering from these neurodegenerative conditions.